Patents by Inventor Markus H. Frank
Markus H. Frank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340116Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: ApplicationFiled: December 8, 2022Publication date: October 26, 2023Applicant: Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Publication number: 20230313136Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.Type: ApplicationFiled: March 10, 2023Publication date: October 5, 2023Applicant: Children's Medical Center CorporationInventor: Markus H. Frank
-
Publication number: 20230203153Abstract: Disclosed herein are anti-ABCB5 antibodies possessing superior binding and biological activities, for instance, relative to commercially available ABCB5 antibodies, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-ABCB5 antibodies.Type: ApplicationFiled: April 30, 2021Publication date: June 29, 2023Applicants: Children's Medical Center Corporation, TICEBA GmbH, RHEACELL GmbH & Co., KGInventors: Markus H. Frank, Christoph Ganss, Christoph Maßlo, Mark Andreas Kluth, Jan Reckenbeil
-
Publication number: 20230149469Abstract: The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds.Type: ApplicationFiled: September 19, 2022Publication date: May 18, 2023Applicants: The United States Government as represented by The Department of Veterans Affairs, The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank, Dennis P. Orgill, George F. Murphy
-
Publication number: 20230148432Abstract: Methods and compositions comprising ABCB5+ stem cell to treat hyper-inflammatory disorders, such as acute respiratory distress syndrome (ARDS) are provided. Such compositions may be used to treat, for example, patients with severe COVID19.Type: ApplicationFiled: March 30, 2021Publication date: May 11, 2023Applicants: Children's Medical Center Corporation, TICEBA GmbHInventors: Mark Andreas Kluth, Markus H. Frank, Christoph Ganss
-
Publication number: 20230136997Abstract: The present invention is directed to methods and compositions for treating Glioblastoma multiforme (GBM). The risk of developing therapy resistant GBM may be assessed by detecting the presence of ABCB5 in the GBM cells. Therapeutic interventions utilizing an ABCB5 blockade to sensitize the GBM cells to therapeutic agents such as temozolomide are provided.Type: ApplicationFiled: April 14, 2021Publication date: May 4, 2023Applicants: Children's Medical Center Corporation, The Brigham and Woman's Hospital, Inc.Inventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 11624054Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.Type: GrantFiled: July 9, 2018Date of Patent: April 11, 2023Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventor: Markus H. Frank
-
Patent number: 11542328Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: GrantFiled: June 10, 2019Date of Patent: January 3, 2023Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 11446331Abstract: The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds.Type: GrantFiled: May 9, 2014Date of Patent: September 20, 2022Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The United States Government as Represented by the Department of Veterans AffairsInventors: Markus H. Frank, Natasha Y. Frank, Dennis P. Orgill, George F. Murphy
-
Publication number: 20220241339Abstract: The invention relates to methods for treating liver disease. For instance a method for treating liver fibrosis in a subject in a subject in need thereof, comprising injecting an isolated population of ABCB5+ stem cells into the subject in an effective amount to treat liver fibrosis in the subject is provided. Methods for inducing liver tissue generation in a subject in need thereof by injecting an isolated population of ABCB5+ stem cells into the subject in an effective amount to generate liver tissue are also provided.Type: ApplicationFiled: April 24, 2020Publication date: August 4, 2022Inventors: Markus H. Frank, Christoph Ganss, Mark Andreas Kiuth
-
Publication number: 20220184136Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5? positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.Type: ApplicationFiled: March 27, 2020Publication date: June 16, 2022Applicants: Children's Medical Center Corporation, TICEBA GmbHInventors: Markus H. Frank, Mark Andreas Kluth, Christoph Ganss
-
Publication number: 20220118024Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.Type: ApplicationFiled: September 27, 2021Publication date: April 21, 2022Applicants: The United States of America as represented by the Department of Veterans Affairs, Schepens Eye Research Institute, Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
-
Publication number: 20210355210Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: ApplicationFiled: June 10, 2019Publication date: November 18, 2021Applicant: Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 11129854Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.Type: GrantFiled: October 30, 2017Date of Patent: September 28, 2021Assignees: Schepens Eye Research Institute, Children's Medical Center Corporation, The United States of America as Represented by the Department of Veterans AffairsInventors: Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
-
Publication number: 20210188999Abstract: The present invention is directed to methods and compositions for modulating ABCB5+ stem cell activity. The invention also relates to assays and reagents for manipulating and characterizing compounds that modulate ABCB5+ cell signaling.Type: ApplicationFiled: April 25, 2019Publication date: June 24, 2021Applicant: Children's Medical Center CorporationInventor: Markus H. Frank
-
Publication number: 20210095254Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.Type: ApplicationFiled: March 30, 2020Publication date: April 1, 2021Applicants: Children's Medical Center Corporation, TICEBA GmbHInventors: Markus H. Frank, Andreas Kluth, Christoph Ganss
-
Publication number: 20200385464Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: ApplicationFiled: June 10, 2019Publication date: December 10, 2020Applicant: Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 10316085Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: GrantFiled: September 28, 2015Date of Patent: June 11, 2019Assignee: Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Publication number: 20180320131Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.Type: ApplicationFiled: July 9, 2018Publication date: November 8, 2018Inventor: Markus H. Frank
-
Patent number: 10017738Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.Type: GrantFiled: March 15, 2013Date of Patent: July 10, 2018Assignee: Children's Medical Center CorporationInventor: Markus H. Frank